Every 424B that Cingulate Inc. (CING) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CING filings page.
Cingulate Inc. is registering up to 4,208,711 shares of its common stock for resale by selling stockholders. The shares consist of (i) 2,147,472 issued common shares, (ii) 191,824 shares issued upon conversion of Preferred Stock, and (iii) 1,869,415 shares issuable upon exercise of a warrant. The company will receive no proceeds from resales by the selling stockholders; however, cash exercise of the warrant could yield approximately $9.4 million to the company. The prospectus discloses a Private Placement that raised approximately $12.0 million in aggregate gross proceeds and includes standard lock-up and standstill provisions for the purchasers.
Cingulate Inc. registers for resale up to 3,500,000 additional shares of common stock to be offered by Lincoln Park Capital Fund, LLC under a purchase agreement providing up to $25.0 million of committed equity financing.
The registration covers shares the company may elect to issue and sell to Lincoln Park under a July 21, 2025 Purchase Agreement; the company will control timing and may receive proceeds only if it sells Purchase Shares to Lincoln Park. Shares outstanding were 11,594,679 as of March 13, 2026; the prospectus shows an illustrative post-issuance count of 15,094,679 assuming sale of all 3,500,000 additional shares.
Cingulate Inc. is registering common stock with an aggregate offering price of $100,000,000 for sale at-the-market through A.G.P./Alliance Global Partners pursuant to an At The Market Sales Agreement dated March 24, 2026.
The prospectus supplement states sales may be made on Nasdaq or other U.S. trading markets, A.G.P. will act as sales agent (entitled to a 3.0% commission) and the company intends to use net proceeds to advance CTx-1301 regulatory, development, manufacturing and commercialization activities and for general corporate purposes.
The company with Nasdaq symbol CING filed a prospectus supplement that permits at-the-market sales of its common stock with an aggregate offering price of up to $8,840,000 through H.C. Wainwright & Co. under an existing sales agreement. This updates the capacity available under Form S-3 General Instruction I.B.6 and follows earlier sales of common stock with an aggregate sales price of $15,145,503.74 under the prior prospectus.
As of January 12, 2026, the public float was $37,286,229.76, based on 7,339,809 shares held by non-affiliates at a price of $5.08 per share, while the last reported sale price on the Nasdaq Capital Market was $4.87 per share. Over the 12 months up to this supplement, the company sold securities with an aggregate market value of $3,588,312.46 under the same Form S-3 instruction.